Treating chronic urticaria refractory to H1-antihistamines
in Russia: data from the AWARE study

Inna Danilycheva; Alexander Emelyanov; Raisa Meshkova; Olga Ukhanova; Azat Abdrakhmanov; Loliana Litvin

doi:10.5114/ada.2022.117556

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2022
vol. 39

Send email

Copy url:

abstract:

Original paper

Treating chronic urticaria refractory to H1-antihistamines in Russia: data from the AWARE study

Inna Danilycheva

¹

,

Alexander Emelyanov

²

,

Raisa Meshkova

³

,

Olga Ukhanova

⁴

,

Azat Abdrakhmanov

⁵

,

Loliana Litvin

⁶

Department of Allergology and Immunotherapy, NRC Institute of Immunology FMBA of Russia, Moscow, Russia
Department of Respiratory Medicine and Allergy, North-Western Medical University, Saint Petersburg, Russia
Department of Clinical Immunology and Allergology, State Medical University, Smolensk, Russia
State Budgetary Healthcare Institution of Stavropol Territory, Stavropol Regional Clinical Hospital, Stavropol, Russia
Department of Dermatovenereology, Kazan State Medical University, Kazan, Russia
Novartis Pharma LLC, Moscow, Russia

Adv Dermatol Allergol 2022; XXXIX (3): 509-516

DOI: https://doi.org/10.5114/ada.2022.117556

Online publish date: 2022/07/14

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Danilycheva I, Emelyanov A, Meshkova R, Ukhanova O, Abdrakhmanov A, Litvin L. Treating chronic urticaria refractory to H1-antihistamines
in Russia: data from the AWARE study. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2022;39(3):509-516. doi:10.5114/ada.2022.117556.

APA

Danilycheva, I., Emelyanov, A., Meshkova, R., Ukhanova, O., Abdrakhmanov, A.,  & Litvin, L. (2022). Treating chronic urticaria refractory to H1-antihistamines
in Russia: data from the AWARE study. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 39(3), 509-516. https://doi.org/10.5114/ada.2022.117556

Chicago

Danilycheva, Inna, Alexander Emelyanov, Raisa Meshkova, Olga Ukhanova, Azat Abdrakhmanov,  and Loliana Litvin. 2022. "Treating chronic urticaria refractory to H1-antihistamines
in Russia: data from the AWARE study". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 39 (3): 509-516. doi:10.5114/ada.2022.117556.

Harvard

Danilycheva, I., Emelyanov, A., Meshkova, R., Ukhanova, O., Abdrakhmanov, A.,  and Litvin, L. (2022). Treating chronic urticaria refractory to H1-antihistamines
in Russia: data from the AWARE study. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 39(3), pp.509-516. https://doi.org/10.5114/ada.2022.117556

MLA

Danilycheva, Inna et al. "Treating chronic urticaria refractory to H1-antihistamines
in Russia: data from the AWARE study." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 39, no. 3, 2022, pp. 509-516. doi:10.5114/ada.2022.117556.

Vancouver

Danilycheva I, Emelyanov A, Meshkova R, Ukhanova O, Abdrakhmanov A, Litvin L. Treating chronic urticaria refractory to H1-antihistamines
in Russia: data from the AWARE study. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2022;39(3):509-516. doi:10.5114/ada.2022.117556.

Introduction
Data on burden and treatment outcomes of chronic spontaneous urticaria (CSU) in Russia are limited. Poor adherence to recommended treatments can lead to suboptimal management of CSU patients. Aim: To understand disease burden, treatment algorithms, and outcomes of CSU in the Russian cohort of the AWARE study.

Material and methods
AWARE was a global prospective, non-interventional study of chronic urticaria in the real-world setting. Adult patients with H1-antihistamines (H1AH)-refractory CSU for ≥ 2 months were included. Disease characteristics, quality of life (QoL), healthcare resource utilisation (HRU), and pharmacological treatments were observed during the 2-year study period.

Results
Of the 135 patients enrolled from Russia, 121 completed the study. Pre-baseline, ~37% of patients were managed with non-recommended treatments (33% treated with sedative H1AH; 4% with other non-recommended treatments) and 28.2% of patients were not treated for CSU. There was a reduction in the use of sedative H1AH during the study (0.9% of patients treated with sedative H1AHs at Year 2). Decreased disease activity was seen as early as 3 months and continued to improve over 2 years (Urticaria Activity Score over 7 days (UAS7): 20.2 at baseline (n = 124) to 10.1, 7.1, and 3.2 at month 3 (n = 118), 12 (n = 109), and 24 (n = 109), respectively). This corresponded with QoL improvements (dermatology life quality index (DLQI) score: 10.3 at baseline to 5.4, 3.6, and 2.3 at Month 3 (n = 75), 12 (n = 98), and 24 (n = 92), respectively), and reduced angioedema and hives throughout the study.

Conclusions
The burden of CSU in Russia is high, contributing to increased HRU. Guideline-recommended treatments and systematic escalation of therapy to achieve complete symptom control can improve management of patients with CSU.

keywords:

Treating chronic urticaria refractory to H1-antihistamines in Russia: data from the AWARE study

Inna Danilycheva 1 , Alexander Emelyanov 2 , Raisa Meshkova 3 , Olga Ukhanova 4 , Azat Abdrakhmanov 5 , Loliana Litvin 6

angioedema, AWARE, epidemiology, quality of life, treatment guidelines, urticaria

Inna Danilycheva

¹

,

Alexander Emelyanov

²

,

Raisa Meshkova

³

,

Olga Ukhanova

⁴

,

Azat Abdrakhmanov

⁵

,

Loliana Litvin

⁶